[A successful topical administration of prostaglandin E2 (PGE2) for the prophylaxis of chemotherapy associated oral mucosal lesions in a case of monocytic leukemia].
D000287:Administration, Topical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003561:Cytarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000009:adverse effects; D015232:Dinoprostone; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D015122:Mercaptopurine / Q000009:adverse effects; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects; D011458:Prostaglandins E / Q000008:administration & dosage*; D013280:Stomatitis / Q000139:chemically induced / Q000517:prevention & control*
D011458:Prostaglandins E; D003561:Cytarabine; D011239:Prednisolone; D015122:Mercaptopurine; D015232:Dinoprostone; D003630:Daunorubicin